已发表的部分文献: 标题:Determinants for efficient editing with Cas9-mediated recombineering in Escherichia coli.作者:Choudhury A, Fankhauser RG, Freed EF, Oh EJ, Morgenthaler AB, Bassalo M, Copley SD, Kaar JL, Gill RT;杂志名称:ACS Synth Biol 标题:Improved alpharetrovirus-based Gag.MS2 particles for efficient and transient delivery of CRISPR/Cas9 into target cells作者:Baron, Y. et. al.;杂志名称:Molecular Therapy: Nucleic Acid 标题:[Levels of sgRNA as a Major Factor Affecting CRISPRi Knockdown Efficiency in K562 Cells].作者:Wang Y, Xie Y, Dong ZC, Jiang XJ, Gong P, Lu J, Wan F;杂志名称:Mol Biol (Mosk) 标题:A Scalable High-Throughput Isoelectric Fractionation Platform for Extracellular Nanocarriers: Comprehensive and Bias-Free Isolation of Ribonucleoproteins from Plasma, Urine, and Saliva.作者:Sharma H, Yadav V, D'Souza-Schorey C, Go DB, Senapati S, Chang HC;杂志名称:ACS Nano Epigentek 公司是全球领先的表观遗传学相关研究的技术创新者和产品开发供应商。开发了超过700多个专利产品,为表观遗传学方面的研究和新药研发提供全面系统的解决方案,涵盖样品制备、DNA/RNA甲基化(5-mc, 5-hmc, 5-fc, m6A)/DNMT分析、ChIP、组蛋白甲基化/乙酰化/去乙酰化/磷酸化/SUMO-等领域,提供小分子抑制剂、蛋白质、抗体、以及分析试剂盒产品。